Static Physicians Global Assessment (sPGA) of 0 or 1 is associated with improved patient reported outcomes in patients with moderate to severe psoriasis in a phase 2 trial of ixekizumab - 16/03/14
Baojin Zhu, PhD, Eli Lillly and Company, Indianapolis, IN, United States; Craig Leonardi, MD, St. Louis University School of Medicine, St. Louis, MO, United States; Emily Edson-Heredia, MPH, Eli Lilly and Company, Indianapolis, IN, United States; Gregory Cameron, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Kenneth Gordon, MD, Northwestern University, Feinberg School of Medicine, Chicago, IL, United States; Michael Heffernan, MD, Eli Lilly and Company, Indianapolis, IN, United States; Subhashis Banerjee, MD, Eli Lilly and Company, Indianapolis, IN, United States; Tomoko Maeda-Chubachi, MD, Eli Lilly and Company, Indianapolis, IN, United States
Le texte complet de cet article est disponible en PDF.| Sponsored 100% by Eli Lilly and Company. |
Vol 70 - N° 5S1
P. AB190 - mai 2014 Retour au numéro
Article précédent
- Similar preclinical pharmacokinetics of the proposed biosimilar adalimumab GP2017 and originator adalimumab upon single and multiple administrations
- Study design and baseline characteristics from a phase 3, randomized, double-blind study of adalimumab versus methotrexate treatment in pediatric patients with chronic plaque psoriasis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?